Ranisan® 75 mg
coated tablets
![RanisanRR 75 mg](javascript:obrazek_big("http://promedcs.cz//en/../img/baleni/600_ranisan_75(1).jpg", "en"); "RanisanRR 75 mg")
- Manufacturer:
- PRO.MED.CS Praha a.s.
- Marketing authorisation holder:
- PRO.MED.CS Praha a.s.
- Composition:
- Ranitidini hydrochloridum 84 mg equivalent to ranitidine 75.26 mg in 1 coated tablet.
- Indication group:
- antiulceric agent, H2-receptor antagonist
![RanisanRR 75 mg](javascript:obrazek_big("http://promedcs.cz//en/../img/letaky/600_let_ranisan75(1).jpg", "en"); "RanisanRR 75 mg")
Characteristics:
Ranisan® 75 mg belongs to the group of agents decreasing the formation of acid gastric juice. It is quickly absorbed in the intestine and its effect is not influenced by the contemporary content of the stomach. After the administration of one tablet, the effect commences within half an hour and lasts for about 10 to 12 hours. In renal insufficiency, there is significant prolongation of its effect.
Indications:
The preparation is used to alleviate the signs of heartburn, gastric hyperacidity, and nausea. The preparation can be taken by adults over 18 years of age. Young persons over 16 years of age can be administered the preparation only when recommended by the physician.
Contraindications:
Ranisan® 75 mg must not be administered to patients with hypersensitivity to its components and in the malignant nature of ulcer disease. Particularly serious reasons must be present for administering the preparation during pregnancy and lactation; in this case it is possible to take this preparation only with the physician’s consent. When becoming pregnant during therapy, the physician is to be informed immediately. The preparation is not administered to patients under 16 years of age.
Undesirable effects:
he preparation Ranisan® 75 mg is usually well tolerated. The frequency in various undesirable effects is different. There may be headaches, vertigoes, dry mouth, nausea, flatulence, constipation, diarrhoea, and loss of appetite. In exceptional cases, there may be cramps, transient impotence, disorders in menstruation, and hair loss.
Laboratory findings rarely show an increase in liver enzymes and changes in blood count. Inform your physician about the occurrence of any undesirable effects during the therapy. If hypersensitivity to Ranisan® 75 mg occurs, which is manifested by, e.g., skin rashes or digestive disorders, it is necessary to discontinue the treatment and inform the attending physician.
Interactions:
The effects of the preparation Ranisan® 75 mg and other concomitantly administered drugs may interact. Ranisan® 75 mg may influence the effect of some drugs (e.g., procainamide, diazepam, theophylline) by changing their renal excretion. Your physician is to be informed about all drugs which you concomitantly take, or which you are going to take, whether they are available for medical prescription or over the counter.
Caution:
Patients diagnosed as having ulcer disease, serious renal and hepatic disorders, patient of the middle or higher age in whom weight loss occurred in connection with digestive troubles (dyspeptic syndrome), difficult swallowing, those concomitantly receiving other medication, should consult the administration of the preparation with their physicians. Without consultation with the physician, take Ranisan® 75 mg for a period not longer than 5 days. If the symptoms do not disappear or there are undesirable effects or unusual reactions, consult the physician.
Dosage:
If the physician does not recommend otherwise, adults usually take 1 tablet during troubles. This dose should bring relief for a period of about 9 hours. In the course of 24 hours, two tablets can be taken. The total period of treatment without consulting the physician should not exceed 5 days. The dose for younger persons over 16 years is determined by the physician. The preparation is not to be administered to patients under 16 year of age.
Package:
10 coated tablets.
Carefully read the accompanying information before use.